



26 October 2011

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel comments on ruling issued by the European Court of Justice (ECJ) on patents involving human embryonic stem cells

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, wishes to comment on the ruling issued on Tuesday 18th October by the European Court of Justice prohibiting the patentability of human embryonic stem cells.

The Court ruled that patents would not be granted on stem cells removed from human embryos if the embryos are destroyed in the process. However, this does not prevent the filing of patent applications relating to process and use claims, providing an alternative strategy for gaining product protection in EU countries.

The majority of cell-based work currently ongoing at Angel, and the work that the Company is seeking to secure in the future, is either based on the use of adult stem cells or autologous cell programmes where the patients' own cells are used for the clinical procedure. Neither of these technologies is affected by the EU ruling.

Dr Paul Harper, Chairman of Angel, said:

"We believe that the significant market opportunity for the cell therapy services we offer will be derived in North America and this will not be affected by this ruling. There has also been clear commitment by the UK Government on the importance of cell therapies, including stem cells, to the future of the UK biopharmaceutical industry.

Whilst the Company sees the development of its cell therapy services as a key aspect of its strategy for growth in the future, non-cell therapy based work currently comprises the bulk of Angel's revenues. This ruling has no impact on the expansion into Cramlington."

For further information:

Angel Biotechnology Holdings plc

Gordon Sherriff, Chief Operating Officer
Lorna Peers, Finance Director

+44 (0) 131 445 6077
www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Freat / Elliot Berg

+44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce

+44 (0) 20 7947 4350



Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon

ariane.comstive@communications-portfolio.co.uk

+44 (0) 20 7536 2028 / 2029

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 32 people, and a site in Cramlington, near Newcastle-upon-Tyne, which is expected to be commissioned by the end of 2011, initially employing up to 10 people.

More information is available at www.angelbio.com .

- Ends -